Dr. Alexa - Digital Cancer Therapy Assistant
#DigitalHealth #SpeechAssistantforHealth #DigitalCancerAssistant
Digitalization and technical progress are bringing new opportunities - also for the healthcare system. Work with Takeda on innovative approaches for digital therapy support and address the question: How can speech assistants help manage chronic cancer and provide positive effects for the patient, the relatives, the treatment team and, through a more favorable course of disease, for payers and society?
✅ Completed 🏁 Winner Congrats to Synthesis & Medical Informations Group
🏆 Prize 15,000 € prize pool in the overall DE 4.0 project + invitation to the Federal Chancellery + promotion of further implementation + chance for further cooperation with Takeda
What is in it for you?
In order to give the developed solutions, the greatest possible appreciation and attention, all solutions of the final teams will be published in a joint publication! This way, they can be regarded as recommendations for action or instruments for politics, economy, and society and at the same time be pursued further.
In addition, the best six teams of the overall DEUTSCHLAND 4.0 project will receive prize money totaling 15.000€, which will be divided equally among all six teams.
Besides prize money we have many exciting opportunities for you:
- An invitation to the Federal Chancellery for a personal interview with Dorothee Bär for the award-winning teams
- Contact to experts from business and science
- Further collaborations with the company of the use case with the prospect of implementing the project
- Access to exclusive events and personal mentoring by innovation experts from the Lufthansa Group
- Support for the continuation of your solutions through the Campus Founders' Accelerator Program
- Potential internships with the cooperation partners
Incentives - Takeda
Depending on the result, further collaboration may result and will be discussed at the end of the project.
As a pharmaceutical company, Takeda does not or must not have a primary role in the care of individual patients, but promising applications can be allocated externally and promoted together with Takeda's network.